


IFAB: High-Affinity Antibody to EphA3; Disrupts the Cancer Stem-Cell Niche



EphA3⁺ TARGET CELLS

▪ TUMOR CELLS

▪ STEM CELLS
▪ TUMOR VASCULATURE
▪ STROMA (MDSCs)

CLINICAL SIGNIFICANCE

▪ PATIENT SELECTION
▪ BIOMARKER

▪ DURABLE RESPONSE

- **Cancer stem cells highly resistant to current therapies¹**
- **Targeting stem cells may deliver durable anti-tumor response²**
 - Malignant stem-cell niche in solid tumors
 - Bone-marrow compartment in hematologic malignancies


1. Stem Cells Int. 2018; 2018: 5416923. Published online 2018 Feb 28. doi: 10.1155/2018/5416923

2. Int J Mol Sci. 2017 Dec; 18(12): 2574. Published online 2017 Dec 1. doi: 10.3390/ijms18122574


Phase 1 IFAB Data in Glioblastoma Multiforme (GBM)

Radio-labelled IFAB shows rapid, specific targeting of GBM


No normal tissue uptake of ^{89}Zr -ifabotuzumab



MRI (T1 + C)



^{89}Zr -ifabotuzumab PET



^{18}F -FDG PET

Source: Scott, A., et al. (2021). Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma (OP-0854). *European Journal of Nuclear Medicine and Molecular Imaging* September 24, 2021;48, s299
<https://doi.org/10.1007/s00259-021-05547-1>